Table 2.
Chemical Predicted | Hypergeometric P-value | Rank (percentile) | q-value | Relevant genes in set (number of references) | Citations |
---|---|---|---|---|---|
Estradiol | 4 × 10-10 | 5 (99) | 0 | ESR2(37), PGR(34), MAPK1(14) | [37] |
Raloxifene | 1 × 10-9 | 6 (99) | 0 | ESR2(6), IGF1(5), BCL2(4) | [38] |
Sodium arsenite | 1 × 10-8 | 8 (99) | 0 | JUN(13), MAPK1(9), CCND1(8), FOS(6) | [30] |
Doxorubicin | 7 × 10-7 | 11 (99) | 0 | BCL2(23), MAPK1(14), TNF(10) | [39-42] |
Cadmium | 6 × 10-6 | 13 (99) | 0 | MT2A(14), MT1A(12), MT3(11), MT1(6) | [43] |
Genistein | 3 × 10-5 | 19 (99) | 6 × 10-4 | ESR2(22), PGR (10), MAPK1 (5) | [44-46] |
Diethylstilbestrol | 3 × 10-5 | 22 (98) | 0.001 | ESR2(8), FOS(8), HOXA10(4) | [47,48] |
Fenretinide | 3 × 10-4 | 40 (97) | 0.004 | BCL2(3), ELF3(2), LDHA(2) | [49] |
Bisphenol A | 6 × 10-4 | 47 (96) | 0.01 | PGR(8), ESR2(7), IL4RA(2) | [37] |
Zinc | 9 × 10-4 | 53 (96) | 0.01 | MT3(18), MT2A(13), MT1A(11) | [50-53] |
Shown in the table are a subset of the highly ranked chemicals (p < 0.001) that were predicted to have association with prostate cancer gene expression and had evidence of association with the MeSH term "Prostatic Neoplasms" as in the CTD. The 1st column represents the chemical predicted and the 2nd and 3rd columns show the hypergeometric p-value and ranking. The 4th column shows q-value derived from random samples of genes. The 5th column shows the notable genes in the chemical-gene set that were differentially expressed. The 6th column contains references for the prostate cancer and chemical association found from the CTD.